CN113567682A - 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 - Google Patents
一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 Download PDFInfo
- Publication number
- CN113567682A CN113567682A CN202110835011.1A CN202110835011A CN113567682A CN 113567682 A CN113567682 A CN 113567682A CN 202110835011 A CN202110835011 A CN 202110835011A CN 113567682 A CN113567682 A CN 113567682A
- Authority
- CN
- China
- Prior art keywords
- disease
- alzheimer
- artificial sequence
- tcr
- marker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 115
- 239000003550 marker Substances 0.000 title claims abstract description 33
- 238000001514 detection method Methods 0.000 title claims abstract description 21
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 19
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 17
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 13
- 108091008874 T cell receptors Proteins 0.000 claims description 9
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000000758 substrate Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012165 high-throughput sequencing Methods 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 7
- 238000003745 diagnosis Methods 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 4
- 238000007405 data analysis Methods 0.000 abstract description 3
- 238000012545 processing Methods 0.000 abstract description 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 28
- NCQMBSJGJMYKCK-ZLUOBGJFSA-N Ala-Ser-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O NCQMBSJGJMYKCK-ZLUOBGJFSA-N 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 16
- 206010012289 Dementia Diseases 0.000 description 11
- 108091008875 B cell receptors Proteins 0.000 description 9
- 238000002600 positron emission tomography Methods 0.000 description 9
- VJVQKGYHIZPSNS-FXQIFTODSA-N Ala-Ser-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCN=C(N)N VJVQKGYHIZPSNS-FXQIFTODSA-N 0.000 description 7
- 208000012902 Nervous system disease Diseases 0.000 description 7
- 208000025966 Neurological disease Diseases 0.000 description 7
- 206010039966 Senile dementia Diseases 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- RFDHKPSHTXZKLL-IHRRRGAJSA-N Glu-Gln-Phe Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CCC(=O)O)N RFDHKPSHTXZKLL-IHRRRGAJSA-N 0.000 description 6
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 6
- 238000005070 sampling Methods 0.000 description 6
- RCEHMXVEMNXRIW-IRIUXVKKSA-N Thr-Gln-Tyr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N)O RCEHMXVEMNXRIW-IRIUXVKKSA-N 0.000 description 5
- 210000004556 brain Anatomy 0.000 description 5
- 230000006735 deficit Effects 0.000 description 5
- 238000002595 magnetic resonance imaging Methods 0.000 description 5
- QYXNFROWLZPWPC-FXQIFTODSA-N Asn-Glu-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QYXNFROWLZPWPC-FXQIFTODSA-N 0.000 description 4
- 206010003694 Atrophy Diseases 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 230000037444 atrophy Effects 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 230000003920 cognitive function Effects 0.000 description 4
- 238000013399 early diagnosis Methods 0.000 description 4
- 108010049041 glutamylalanine Proteins 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 102000013498 tau Proteins Human genes 0.000 description 4
- 108010026424 tau Proteins Proteins 0.000 description 4
- QOCFFCUFZGDHTP-NUMRIWBASA-N Asp-Thr-Gln Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O QOCFFCUFZGDHTP-NUMRIWBASA-N 0.000 description 3
- 208000024806 Brain atrophy Diseases 0.000 description 3
- 102000004878 Gelsolin Human genes 0.000 description 3
- 108090001064 Gelsolin Proteins 0.000 description 3
- YYPFZVIXAVDHIK-IUCAKERBSA-N Gly-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CN YYPFZVIXAVDHIK-IUCAKERBSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 3
- 230000003941 amyloidogenesis Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 238000003759 clinical diagnosis Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 210000003478 temporal lobe Anatomy 0.000 description 3
- 108010061238 threonyl-glycine Proteins 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 208000006888 Agnosia Diseases 0.000 description 2
- 241001047040 Agnosia Species 0.000 description 2
- TVUFMYKTYXTRPY-HERUPUMHSA-N Ala-Trp-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CO)C(O)=O TVUFMYKTYXTRPY-HERUPUMHSA-N 0.000 description 2
- YIDFBWRHIYOYAA-LKXGYXEUSA-N Asp-Ser-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(O)=O YIDFBWRHIYOYAA-LKXGYXEUSA-N 0.000 description 2
- CLODWIOAKCSBAN-BQBZGAKWSA-N Gly-Arg-Asp Chemical compound NC(N)=NCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O CLODWIOAKCSBAN-BQBZGAKWSA-N 0.000 description 2
- GBYYQVBXFVDJPJ-WLTAIBSBSA-N Gly-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)CN)O GBYYQVBXFVDJPJ-WLTAIBSBSA-N 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 206010021034 Hypometabolism Diseases 0.000 description 2
- 241000880493 Leptailurus serval Species 0.000 description 2
- DEDANIDYQAPTFI-IHRRRGAJSA-N Pro-Asp-Tyr Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DEDANIDYQAPTFI-IHRRRGAJSA-N 0.000 description 2
- 206010040030 Sensory loss Diseases 0.000 description 2
- FIXILCYTSAUERA-FXQIFTODSA-N Ser-Ala-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FIXILCYTSAUERA-FXQIFTODSA-N 0.000 description 2
- YQHZVYJAGWMHES-ZLUOBGJFSA-N Ser-Ala-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YQHZVYJAGWMHES-ZLUOBGJFSA-N 0.000 description 2
- AEGUWTFAQQWVLC-BQBZGAKWSA-N Ser-Gly-Arg Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O AEGUWTFAQQWVLC-BQBZGAKWSA-N 0.000 description 2
- QYBRQMLZDDJBSW-AVGNSLFASA-N Ser-Tyr-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O QYBRQMLZDDJBSW-AVGNSLFASA-N 0.000 description 2
- WAPFQMXRSDEGOE-IHRRRGAJSA-N Tyr-Glu-Gln Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O WAPFQMXRSDEGOE-IHRRRGAJSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000005006 adaptive immune system Anatomy 0.000 description 2
- 201000007201 aphasia Diseases 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 108010060035 arginylproline Proteins 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000001037 epileptic effect Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010089804 glycyl-threonine Proteins 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011493 immune profiling Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108010026333 seryl-proline Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- IAVCEBMLYVGBLA-UHFFFAOYSA-N 2-[1-[6-[2-fluoroethyl(methyl)amino]naphthalen-2-yl]ethylidene]propanedinitrile Chemical compound C1=C(C(C)=C(C#N)C#N)C=CC2=CC(N(CCF)C)=CC=C21 IAVCEBMLYVGBLA-UHFFFAOYSA-N 0.000 description 1
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 1
- PBAMJJXWDQXOJA-FXQIFTODSA-N Ala-Asp-Arg Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N PBAMJJXWDQXOJA-FXQIFTODSA-N 0.000 description 1
- LSLIRHLIUDVNBN-CIUDSAMLSA-N Ala-Asp-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN LSLIRHLIUDVNBN-CIUDSAMLSA-N 0.000 description 1
- XYTNPQNAZREREP-XQXXSGGOSA-N Ala-Glu-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XYTNPQNAZREREP-XQXXSGGOSA-N 0.000 description 1
- WMYJZJRILUVVRG-WDSKDSINSA-N Ala-Gly-Gln Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O WMYJZJRILUVVRG-WDSKDSINSA-N 0.000 description 1
- BEMGNWZECGIJOI-WDSKDSINSA-N Ala-Gly-Glu Chemical compound [H]N[C@@H](C)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O BEMGNWZECGIJOI-WDSKDSINSA-N 0.000 description 1
- PCIFXPRIFWKWLK-YUMQZZPRSA-N Ala-Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](C)N PCIFXPRIFWKWLK-YUMQZZPRSA-N 0.000 description 1
- VNYMOTCMNHJGTG-JBDRJPRFSA-N Ala-Ile-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O VNYMOTCMNHJGTG-JBDRJPRFSA-N 0.000 description 1
- GFEDXKNBZMPEDM-KZVJFYERSA-N Ala-Met-Thr Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFEDXKNBZMPEDM-KZVJFYERSA-N 0.000 description 1
- MSWSRLGNLKHDEI-ACZMJKKPSA-N Ala-Ser-Glu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O MSWSRLGNLKHDEI-ACZMJKKPSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- VRTOMXFZHGWHIJ-KZVJFYERSA-N Ala-Thr-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O VRTOMXFZHGWHIJ-KZVJFYERSA-N 0.000 description 1
- KTXKIYXZQFWJKB-VZFHVOOUSA-N Ala-Thr-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O KTXKIYXZQFWJKB-VZFHVOOUSA-N 0.000 description 1
- AETQNIIFKCMVHP-UVBJJODRSA-N Ala-Trp-Arg Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O AETQNIIFKCMVHP-UVBJJODRSA-N 0.000 description 1
- AOAKQKVICDWCLB-UWJYBYFXSA-N Ala-Tyr-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N AOAKQKVICDWCLB-UWJYBYFXSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- DFCIPNHFKOQAME-FXQIFTODSA-N Arg-Ala-Asn Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(O)=O DFCIPNHFKOQAME-FXQIFTODSA-N 0.000 description 1
- ZTKHZAXGTFXUDD-VEVYYDQMSA-N Arg-Asn-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZTKHZAXGTFXUDD-VEVYYDQMSA-N 0.000 description 1
- MFAMTAVAFBPXDC-LPEHRKFASA-N Arg-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O MFAMTAVAFBPXDC-LPEHRKFASA-N 0.000 description 1
- MZRBYBIQTIKERR-GUBZILKMSA-N Arg-Glu-Gln Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O MZRBYBIQTIKERR-GUBZILKMSA-N 0.000 description 1
- UZSQXCMNUPKLCC-FJXKBIBVSA-N Arg-Thr-Gly Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O UZSQXCMNUPKLCC-FJXKBIBVSA-N 0.000 description 1
- WONGRTVAMHFGBE-WDSKDSINSA-N Asn-Gly-Gln Chemical compound C(CC(=O)N)[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N WONGRTVAMHFGBE-WDSKDSINSA-N 0.000 description 1
- ZUFPUBYQYWCMDB-NUMRIWBASA-N Asn-Thr-Glu Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZUFPUBYQYWCMDB-NUMRIWBASA-N 0.000 description 1
- OERMIMJQPQUIPK-FXQIFTODSA-N Asp-Arg-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O OERMIMJQPQUIPK-FXQIFTODSA-N 0.000 description 1
- GVPSCJQLUGIKAM-GUBZILKMSA-N Asp-Arg-Arg Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O GVPSCJQLUGIKAM-GUBZILKMSA-N 0.000 description 1
- OMMIEVATLAGRCK-BYPYZUCNSA-N Asp-Gly-Gly Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)NCC(O)=O OMMIEVATLAGRCK-BYPYZUCNSA-N 0.000 description 1
- PWAIZUBWHRHYKS-MELADBBJSA-N Asp-Phe-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)NC(=O)[C@H](CC(=O)O)N)C(=O)O PWAIZUBWHRHYKS-MELADBBJSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- REJJNXODKSHOKA-ACZMJKKPSA-N Gln-Ala-Asp Chemical compound C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N REJJNXODKSHOKA-ACZMJKKPSA-N 0.000 description 1
- SNLOOPZHAQDMJG-CIUDSAMLSA-N Gln-Glu-Glu Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SNLOOPZHAQDMJG-CIUDSAMLSA-N 0.000 description 1
- XJKAKYXMFHUIHT-AUTRQRHGSA-N Gln-Glu-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)N)N XJKAKYXMFHUIHT-AUTRQRHGSA-N 0.000 description 1
- GLEGHWQNGPMKHO-DCAQKATOSA-N Gln-His-Glu Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@H](CCC(=O)N)N GLEGHWQNGPMKHO-DCAQKATOSA-N 0.000 description 1
- PBYFVIQRFLNQCO-GUBZILKMSA-N Gln-Pro-Gln Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(O)=O PBYFVIQRFLNQCO-GUBZILKMSA-N 0.000 description 1
- HMIXCETWRYDVMO-GUBZILKMSA-N Gln-Pro-Glu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O HMIXCETWRYDVMO-GUBZILKMSA-N 0.000 description 1
- ININBLZFFVOQIO-JHEQGTHGSA-N Gln-Thr-Gly Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CCC(=O)N)N)O ININBLZFFVOQIO-JHEQGTHGSA-N 0.000 description 1
- WPJDPEOQUIXXOY-AVGNSLFASA-N Gln-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O WPJDPEOQUIXXOY-AVGNSLFASA-N 0.000 description 1
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 1
- MXOODARRORARSU-ACZMJKKPSA-N Glu-Ala-Ser Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCC(=O)O)N MXOODARRORARSU-ACZMJKKPSA-N 0.000 description 1
- RCCDHXSRMWCOOY-GUBZILKMSA-N Glu-Arg-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O RCCDHXSRMWCOOY-GUBZILKMSA-N 0.000 description 1
- HUFCEIHAFNVSNR-IHRRRGAJSA-N Glu-Gln-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUFCEIHAFNVSNR-IHRRRGAJSA-N 0.000 description 1
- WNRZUESNGGDCJX-JYJNAYRXSA-N Glu-Leu-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O WNRZUESNGGDCJX-JYJNAYRXSA-N 0.000 description 1
- NJCALAAIGREHDR-WDCWCFNPSA-N Glu-Leu-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O NJCALAAIGREHDR-WDCWCFNPSA-N 0.000 description 1
- OQXDUSZKISQQSS-GUBZILKMSA-N Glu-Lys-Ala Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O OQXDUSZKISQQSS-GUBZILKMSA-N 0.000 description 1
- RFTVTKBHDXCEEX-WDSKDSINSA-N Glu-Ser-Gly Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RFTVTKBHDXCEEX-WDSKDSINSA-N 0.000 description 1
- MXJYXYDREQWUMS-XKBZYTNZSA-N Glu-Thr-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O MXJYXYDREQWUMS-XKBZYTNZSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 1
- GZUKEVBTYNNUQF-WDSKDSINSA-N Gly-Ala-Gln Chemical compound NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(O)=O GZUKEVBTYNNUQF-WDSKDSINSA-N 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- QIZJOTQTCAGKPU-KWQFWETISA-N Gly-Ala-Tyr Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)N[C@H](C([O-])=O)CC1=CC=C(O)C=C1 QIZJOTQTCAGKPU-KWQFWETISA-N 0.000 description 1
- JPXNYFOHTHSREU-UWVGGRQHSA-N Gly-Arg-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN JPXNYFOHTHSREU-UWVGGRQHSA-N 0.000 description 1
- OVSKVOOUFAKODB-UWVGGRQHSA-N Gly-Arg-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N OVSKVOOUFAKODB-UWVGGRQHSA-N 0.000 description 1
- WKJKBELXHCTHIJ-WPRPVWTQSA-N Gly-Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCN=C(N)N WKJKBELXHCTHIJ-WPRPVWTQSA-N 0.000 description 1
- NZAFOTBEULLEQB-WDSKDSINSA-N Gly-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)CN NZAFOTBEULLEQB-WDSKDSINSA-N 0.000 description 1
- LURCIJSJAKFCRO-QWRGUYRKSA-N Gly-Asn-Tyr Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O LURCIJSJAKFCRO-QWRGUYRKSA-N 0.000 description 1
- FZQLXNIMCPJVJE-YUMQZZPRSA-N Gly-Asp-Leu Chemical compound [H]NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O FZQLXNIMCPJVJE-YUMQZZPRSA-N 0.000 description 1
- JUGQPPOVWXSPKJ-RYUDHWBXSA-N Gly-Gln-Phe Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O JUGQPPOVWXSPKJ-RYUDHWBXSA-N 0.000 description 1
- JLJLBWDKDRYOPA-RYUDHWBXSA-N Gly-Gln-Tyr Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 JLJLBWDKDRYOPA-RYUDHWBXSA-N 0.000 description 1
- HFXJIZNEXNIZIJ-BQBZGAKWSA-N Gly-Glu-Gln Chemical compound NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFXJIZNEXNIZIJ-BQBZGAKWSA-N 0.000 description 1
- SOEATRRYCIPEHA-BQBZGAKWSA-N Gly-Glu-Glu Chemical compound [H]NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SOEATRRYCIPEHA-BQBZGAKWSA-N 0.000 description 1
- HQRHFUYMGCHHJS-LURJTMIESA-N Gly-Gly-Arg Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N HQRHFUYMGCHHJS-LURJTMIESA-N 0.000 description 1
- QPTNELDXWKRIFX-YFKPBYRVSA-N Gly-Gly-Gln Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O QPTNELDXWKRIFX-YFKPBYRVSA-N 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- UQJNXZSSGQIPIQ-FBCQKBJTSA-N Gly-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)CN UQJNXZSSGQIPIQ-FBCQKBJTSA-N 0.000 description 1
- PAWIVEIWWYGBAM-YUMQZZPRSA-N Gly-Leu-Ala Chemical compound NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O PAWIVEIWWYGBAM-YUMQZZPRSA-N 0.000 description 1
- GMTXWRIDLGTVFC-IUCAKERBSA-N Gly-Lys-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(O)=O GMTXWRIDLGTVFC-IUCAKERBSA-N 0.000 description 1
- MHZXESQPPXOING-KBPBESRZSA-N Gly-Lys-Phe Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MHZXESQPPXOING-KBPBESRZSA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- DBUNZBWUWCIELX-JHEQGTHGSA-N Gly-Thr-Glu Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O DBUNZBWUWCIELX-JHEQGTHGSA-N 0.000 description 1
- JKSMZVCGQWVTBW-STQMWFEESA-N Gly-Trp-Asn Chemical compound [H]NCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(O)=O JKSMZVCGQWVTBW-STQMWFEESA-N 0.000 description 1
- YDIDLLVFCYSXNY-RCOVLWMOSA-N Gly-Val-Asn Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)CN YDIDLLVFCYSXNY-RCOVLWMOSA-N 0.000 description 1
- VTMLJMNQHKBPON-QWRGUYRKSA-N His-Gly-His Chemical compound C([C@H](N)C(=O)NCC(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 VTMLJMNQHKBPON-QWRGUYRKSA-N 0.000 description 1
- ZHMZWSFQRUGLEC-JYJNAYRXSA-N His-Tyr-Glu Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O ZHMZWSFQRUGLEC-JYJNAYRXSA-N 0.000 description 1
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 1
- JHCVYQKVKOLAIU-NAKRPEOUSA-N Ile-Cys-Val Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)O)N JHCVYQKVKOLAIU-NAKRPEOUSA-N 0.000 description 1
- LGMUPVWZEYYUMU-YVNDNENWSA-N Ile-Glu-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N LGMUPVWZEYYUMU-YVNDNENWSA-N 0.000 description 1
- CDGLBYSAZFIIJO-RCOVLWMOSA-N Ile-Gly-Gly Chemical compound CC[C@H](C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O CDGLBYSAZFIIJO-RCOVLWMOSA-N 0.000 description 1
- ODPKZZLRDNXTJZ-WHOFXGATSA-N Ile-Gly-Phe Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N ODPKZZLRDNXTJZ-WHOFXGATSA-N 0.000 description 1
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 1
- WCNWGAUZWWSYDG-SVSWQMSJSA-N Ile-Thr-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)O)N WCNWGAUZWWSYDG-SVSWQMSJSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- LJHGALIOHLRRQN-DCAQKATOSA-N Leu-Ala-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LJHGALIOHLRRQN-DCAQKATOSA-N 0.000 description 1
- WNGVUZWBXZKQES-YUMQZZPRSA-N Leu-Ala-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O WNGVUZWBXZKQES-YUMQZZPRSA-N 0.000 description 1
- PJYSOYLLTJKZHC-GUBZILKMSA-N Leu-Asp-Gln Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(N)=O PJYSOYLLTJKZHC-GUBZILKMSA-N 0.000 description 1
- IWTBYNQNAPECCS-AVGNSLFASA-N Leu-Glu-His Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IWTBYNQNAPECCS-AVGNSLFASA-N 0.000 description 1
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 1
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
- PELXPRPDQRFBGQ-KKUMJFAQSA-N Lys-Tyr-Asn Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N)O PELXPRPDQRFBGQ-KKUMJFAQSA-N 0.000 description 1
- MDXAULHWGWETHF-SRVKXCTJSA-N Met-Arg-Val Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(=O)N[C@@H](C(C)C)C(O)=O)CCCNC(N)=N MDXAULHWGWETHF-SRVKXCTJSA-N 0.000 description 1
- ZMYHJISLFYTQGK-FXQIFTODSA-N Met-Asp-Asn Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O ZMYHJISLFYTQGK-FXQIFTODSA-N 0.000 description 1
- CIIJWIAORKTXAH-FJXKBIBVSA-N Met-Thr-Gly Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O CIIJWIAORKTXAH-FJXKBIBVSA-N 0.000 description 1
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 1
- 108010079364 N-glycylalanine Proteins 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NKLDZIPTGKBDBB-HTUGSXCWSA-N Phe-Gln-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC1=CC=CC=C1)N)O NKLDZIPTGKBDBB-HTUGSXCWSA-N 0.000 description 1
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 1
- XNMYNGDKJNOKHH-BZSNNMDCSA-N Phe-Ser-Tyr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O XNMYNGDKJNOKHH-BZSNNMDCSA-N 0.000 description 1
- 206010036631 Presenile dementia Diseases 0.000 description 1
- IFMDQWDAJUMMJC-DCAQKATOSA-N Pro-Ala-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O IFMDQWDAJUMMJC-DCAQKATOSA-N 0.000 description 1
- CMOIIANLNNYUTP-SRVKXCTJSA-N Pro-Gln-His Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O CMOIIANLNNYUTP-SRVKXCTJSA-N 0.000 description 1
- DMKWYMWNEKIPFC-IUCAKERBSA-N Pro-Gly-Arg Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O DMKWYMWNEKIPFC-IUCAKERBSA-N 0.000 description 1
- RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 description 1
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 1
- MWMKFWJYRRGXOR-ZLUOBGJFSA-N Ser-Ala-Asn Chemical compound N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)O)CC(N)=O)C)CO MWMKFWJYRRGXOR-ZLUOBGJFSA-N 0.000 description 1
- HRNQLKCLPVKZNE-CIUDSAMLSA-N Ser-Ala-Leu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O HRNQLKCLPVKZNE-CIUDSAMLSA-N 0.000 description 1
- PZZJMBYSYAKYPK-UWJYBYFXSA-N Ser-Ala-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O PZZJMBYSYAKYPK-UWJYBYFXSA-N 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- YQQKYAZABFEYAF-FXQIFTODSA-N Ser-Glu-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQQKYAZABFEYAF-FXQIFTODSA-N 0.000 description 1
- SNVIOQXAHVORQM-WDSKDSINSA-N Ser-Gly-Gln Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O SNVIOQXAHVORQM-WDSKDSINSA-N 0.000 description 1
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 1
- KDGARKCAKHBEDB-NKWVEPMBSA-N Ser-Gly-Pro Chemical compound C1C[C@@H](N(C1)C(=O)CNC(=O)[C@H](CO)N)C(=O)O KDGARKCAKHBEDB-NKWVEPMBSA-N 0.000 description 1
- GZGFSPWOMUKKCV-NAKRPEOUSA-N Ser-Pro-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO GZGFSPWOMUKKCV-NAKRPEOUSA-N 0.000 description 1
- OZPDGESCTGGNAD-CIUDSAMLSA-N Ser-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CO OZPDGESCTGGNAD-CIUDSAMLSA-N 0.000 description 1
- SQHKXWODKJDZRC-LKXGYXEUSA-N Ser-Thr-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQHKXWODKJDZRC-LKXGYXEUSA-N 0.000 description 1
- BEBVVQPDSHHWQL-NRPADANISA-N Ser-Val-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(O)=O BEBVVQPDSHHWQL-NRPADANISA-N 0.000 description 1
- MFQMZDPAZRZAPV-NAKRPEOUSA-N Ser-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N MFQMZDPAZRZAPV-NAKRPEOUSA-N 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 1
- XDARBNMYXKUFOJ-GSSVUCPTSA-N Thr-Asp-Thr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XDARBNMYXKUFOJ-GSSVUCPTSA-N 0.000 description 1
- VGYBYGQXZJDZJU-XQXXSGGOSA-N Thr-Glu-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O VGYBYGQXZJDZJU-XQXXSGGOSA-N 0.000 description 1
- AQAMPXBRJJWPNI-JHEQGTHGSA-N Thr-Gly-Glu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AQAMPXBRJJWPNI-JHEQGTHGSA-N 0.000 description 1
- QQWNRERCGGZOKG-WEDXCCLWSA-N Thr-Gly-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O QQWNRERCGGZOKG-WEDXCCLWSA-N 0.000 description 1
- PAXANSWUSVPFNK-IUKAMOBKSA-N Thr-Ile-Asn Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H]([C@@H](C)O)N PAXANSWUSVPFNK-IUKAMOBKSA-N 0.000 description 1
- AHERARIZBPOMNU-KATARQTJSA-N Thr-Ser-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O AHERARIZBPOMNU-KATARQTJSA-N 0.000 description 1
- CXUFDWZBHKUGKK-CABZTGNLSA-N Trp-Ala-Gly Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(O)=O)=CNC2=C1 CXUFDWZBHKUGKK-CABZTGNLSA-N 0.000 description 1
- PEVVXUGSAKEPEN-AVGNSLFASA-N Tyr-Asn-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O PEVVXUGSAKEPEN-AVGNSLFASA-N 0.000 description 1
- QAYSODICXVZUIA-WLTAIBSBSA-N Tyr-Gly-Thr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O QAYSODICXVZUIA-WLTAIBSBSA-N 0.000 description 1
- OKDNSNWJEXAMSU-IRXDYDNUSA-N Tyr-Phe-Gly Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(O)=O)C1=CC=C(O)C=C1 OKDNSNWJEXAMSU-IRXDYDNUSA-N 0.000 description 1
- LVFZXRQQQDTBQH-IRIUXVKKSA-N Tyr-Thr-Glu Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(O)=O LVFZXRQQQDTBQH-IRIUXVKKSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- VUTHNLMCXKLLFI-LAEOZQHASA-N Val-Asp-Gln Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N VUTHNLMCXKLLFI-LAEOZQHASA-N 0.000 description 1
- VLOYGOZDPGYWFO-LAEOZQHASA-N Val-Asp-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O VLOYGOZDPGYWFO-LAEOZQHASA-N 0.000 description 1
- OVLIFGQSBSNGHY-KKHAAJSZSA-N Val-Asp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C(C)C)N)O OVLIFGQSBSNGHY-KKHAAJSZSA-N 0.000 description 1
- APQIVBCUIUDSMB-OSUNSFLBSA-N Val-Ile-Thr Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C(C)C)N APQIVBCUIUDSMB-OSUNSFLBSA-N 0.000 description 1
- JVGDAEKKZKKZFO-RCWTZXSCSA-N Val-Val-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N)O JVGDAEKKZKKZFO-RCWTZXSCSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010069490 alanyl-glycyl-seryl-glutamic acid Proteins 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010043240 arginyl-leucyl-glycine Proteins 0.000 description 1
- 108010036533 arginylvaline Proteins 0.000 description 1
- 108010077245 asparaginyl-proline Proteins 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- 238000002598 diffusion tensor imaging Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 108010008237 glutamyl-valyl-glycine Proteins 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 108010062266 glycyl-glycyl-argininal Proteins 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010078326 glycyl-glycyl-valine Proteins 0.000 description 1
- 108010033719 glycyl-histidyl-glycine Proteins 0.000 description 1
- 108010077435 glycyl-phenylalanyl-glycine Proteins 0.000 description 1
- 108010010147 glycylglutamine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 108010064235 lysylglycine Proteins 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000020470 nervous system symptom Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 108010031719 prolyl-serine Proteins 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 108010048818 seryl-histidine Proteins 0.000 description 1
- 108010071207 serylmethionine Proteins 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种阿尔茨海默病的外周血TCR标志物及其检测试剂盒和应用。该标志物包括序列为SEQ ID NO.1~50所示的蛋白中的至少一种。本发明基于高通量测序方法,只需要采取少量外周血,提取RNA,通过对样本的处理建立免疫图谱文库,再经过高通量测序和TCR数据分析,首先确定阿尔茨海默病外周血中特征性TCR序列,然后将待测样本测试结果与该特征性TCR序列比对,从而确定是否患有阿尔茨海默病。本发明能够同时比较巨大数量的阿尔茨海默病特异性TCR序列,相比单独检测一种或几种标记物,具有更高的特异性和准确性,提高了诊断效率。
Description
技术领域
本发明属于基因工程技术领域,具体涉及一种阿尔茨海默病的外周血TCR标志物及其检测试剂盒和应用。
背景技术
阿尔茨海默病(Alzheimer Disease,AD)是一种起病隐匿的进行性发展的神经系统退行性疾病。临床上以记忆障碍、失语、失用、失认、视空间技能损害、执行功能障碍以及人格和行为改变等全面性痴呆表现为特征,病因迄今未明。65岁以前发病者,称早老性痴呆;65岁以后发病者称老年性痴呆。
随着人口老龄化加剧,老年痴呆症已经成为日益显著的社会问题。根据国际阿尔茨海默病协会发布的《世界阿尔茨海默病2018年报告》,2018年全球约有5千万老年痴呆患者,预计到2050年将有1.5亿人罹患老年痴呆。据不完全统计,目前中国痴呆症患者超过1000万人,其中有60%为阿尔茨海默症,65岁以上人群发病率为5%,80岁以上发病率超过30%。预计到2050年,中国痴呆患者将超过2000万。
老年痴呆根据其病因主要分为脑变性疾病引起的痴呆(包括阿尔茨海默病、额颞叶痴呆、路易体型、帕金森痴呆综合症等)、脑血管病引起的痴呆和混合型痴呆三大类。阿尔茨海默病的临床诊断主要依据其特殊临床演变过程,并结合有关检查排除引起痴呆的其他器质性疾病,而最终确诊需要病理检验结果。
目前,阿尔茨海默病的临床诊断广泛应用NINCDS-ADRDA诊断标准,由美国国立神经病语言障碍卒中研究所(NINCDS)和阿尔茨海默病及相关疾病协会(ADRDA)建立的NINCDS-ADRDA专题工作组推荐(1984年发表于Neurology杂志),其主要内容如下:
1、诊断标准:
1)临床检查和认知量表测查确定有痴呆。
2)两个或两个以上认知功能缺损,且进行性恶化。
3)无意识障碍。
4)40-90岁起病,多见于65岁以后。
5)排除其他引起进行性记忆和认知功能损害的系统性疾病和脑部疾病。
2、支持标准:
1)特殊性认知功能如言语(失语症)、运动技能(失用症)、知觉(失认症)的进行性损害。
2)日常生活功能损害或行为方式的改变。
3)家庭中有类似疾病史,特别是有神经病理学或实验室证据者。
4)实验室检查腰穿压力正常;
5)脑电图正常或无特殊性的改变如慢波增加;
6)CT或MRI证实有脑萎缩,且随诊检查有进行性加重。
3、排除标准:
1)突然起病或卒中样发作。
2)早期有局灶性神经系统体征,如偏瘫、感觉丧失、视野缺损、共济失调。
3)起病或疾病早期有癫痫发作或步态异常。
NINCDS-ADRDA诊断标准经过多年临床实践,与病理结果有很好的一致性。但该标准强调“认知功能损害程度一定要影响患者日常生活能力和社会活动功能,诊断才能成立”,而且强调要排除其它可能导致痴呆的相关系统或脑部疾病,而后者往往同阿尔茨海默病一样,缺乏明确且易检测的生物学标志物。这给阿尔茨海默病患者的早识别、早诊断带来困难。
针对这一不足,随着阿尔茨海默病相关领域研究的迅速进展,NINCDS-ADRDA诊断标准于2007年进行了修订,一些生物学标志物,包括核磁共振(MRI)示内侧颞叶萎缩,正电子发射断层扫描(PET)可见颞顶叶脑血流下降以及脑脊液中Aβ和tau蛋白的异常改变等,被纳入诊断标准。这提高了阿尔茨海默病诊断的特异性和敏感性,对早期诊断帮助较大:
1、核心标准
1)早期、显著的情景记忆障碍;
2)支持表现内颞叶萎缩:MRI显示海马、内嗅皮质、杏仁核体积缩小(与同年龄人群比较);
3)脑脊液生物标记异常:Aβ42降低、总tau或磷酸化tau蛋白增高,或3者同时存在;
4)PET的特殊表现:如双侧颞叶糖代谢减低,显像剂18F-FDDNP*显示AD病理的改变等;
5)直系亲属中有已证实的常染色体显性遗传导致的阿尔茨海默病。
注:*FDDNP:非甾体类抗炎药物甲氧萘普酸的类似物,在体外证实其与老年斑有很强的亲和力。
2、排除标准
1)病史:突然起病;早期出现下列症状:步态不稳、癫痫、行为异常。
2)临床特点:局灶性神经系统症状体征:偏瘫、感觉缺失、视野损害;早期的锥体外系体征。
3)其它疾病状态严重到足以解释记忆和相关症状:非阿尔茨海默病痴呆;严重的抑郁;脑血管病;中毒或代谢异常(要求特殊检查证实);MRI的FLAIR或T2加权相内颞叶信号异常与感染或血管损害一致。
目前实验室中对阿尔茨海默病的检验技术有:
1、正电子发射断层扫描(PET)
目前诊断阿尔茨海默病最有力的方法。葡萄糖代谢PET(FDG PET)在早期能显示阿尔茨海默病患者边缘系统的代谢下降,对轻度阿尔茨海默病诊断灵敏度达到84%,特异性达到93%。而淀粉样蛋白PET(Amyloid PET)研究发现家族性阿尔茨海默病患者在无症状期未出现脑萎缩和脑代谢减低时,已出现了脑内淀粉样蛋白沉积,说明淀粉样蛋白簇(斑块)有可能是最早出现的生物标志物,然而也有研究指出,非阿尔茨海默病的其它疾病也有可能导致脑补淀粉样蛋白沉积。近年来的最新研究表明,早期临床阿尔茨海默症患者的Tau蛋白PET脑部扫描能准确地预测1-2年后核磁共振测量的脑萎缩的位置,而淀粉样蛋白PET显像未来脑萎缩的位置。然而,PET检测设备稀缺、检测费用昂贵,而且由于血脑屏障的存在,必须直接向中枢神经系统内注射显影液,因此其应用存在相当大的局限性。
2、脑脊液检测
脑脊液标记物包括Aβ42、总tau蛋白(t-tau)和磷酸化的tau蛋白(p-tau)。其中,Aβ42反映了皮层淀粉样蛋白沉积;t-tau蛋白反映了神经变性的密度;p-tau与神经元纤维缠结病理改变相关。这些核心CSF标记物有较高的诊断准确性,在早期(轻度认知损害期,mildcognitive impairment,MCI)的敏感度和特异性可达85-90%。但脑脊液检验存在取样困难,病人痛苦大的显著缺点。
3、外周血检测
外周血标志物包括外周血细胞膜的Aβ42二聚体含量、可抑制Aβ纤维化和解聚Aβ纤维的血浆凝溶胶蛋白(GSN)和GSN主要降解酶MMP3等。但外周血中这些成分含量较低,且目前对于外周血成分是否能够真正代表中枢神经系统的改变,仍存在一定质疑。
4、核磁共振检测(MRI)
其中,结构磁共振(sMRI)可测量区域性或全脑体积大小,反映因细胞损伤、轴突退变、突触失调引起的结构萎缩。最早出现并进行性加重的内侧颞叶结构萎缩可能是AD早期出现的特征性改变。大脑接受刺激后,神经细胞活动、局部脑血流、区域的耗氧量发生改变,功能磁共振(fMRI)通过血流动力学反应与脑神经细胞活动之间的密切关系,可反映神经元和突触功能异常。弥散张量成像(DTI)、T2弛豫时间成像等核磁共振参数,在最近的一些研究中,也展示出了作为阿尔茨海默病早期诊断标准的潜力。然而根据最新诊断标准,迄今为止核磁共振检测还是更适合用于测量和监测阿尔茨海默病的疾病过程,是否适用于疾病的早期诊断还需更多研究进一步验证。
5、基因检测
有研究表明,一些基因型的携带者如APOE4基因,有较高几率罹患阿尔茨海默病。然而,这种传统基因的检测,只能作为一种辅助的风险评估,而无法作为阿尔茨海默病的诊断标准。
综上所述,目前针对阿尔茨海默病的临床诊断,仍然严重依赖于评估性的量表标准,缺乏一种方便、准确且相对廉价的确诊检验手段。
发明内容
针对现有技术中的上述不足,本发明提供一种阿尔茨海默病的外周血TCR标志物及其检测试剂盒和应用,能无创且准确快速的判断待测样本中是否有较高阿尔茨海默病风险患者。
为实现上述目的,本发明解决其技术问题所采用的技术方案是:
一种阿尔茨海默病的外周血TCR标志物,该标志物包括序列为SEQ ID NO.1~50所示的蛋白中的至少一种,具体序列见表1。
表1标志物序列
进一步地,标志物的蛋白序列为SEQ ID NO.1~50所示的序列经取代、缺失和/或替换一个或多个氨基酸后,能实现相同功能的蛋白。
进一步地,标志物为外周血TCR CDR3序列。
上述标志物在制备治疗阿尔茨海默病的制剂中的应用。
进一步地,制剂中包括含有该标志物的T细胞受体,或能表达产生该标志物的T细胞受体的质粒、病毒载体或核酸片段。
一种用于阿尔茨海默病检测的试剂盒,包括能与上述标志物发生特异性结合的抗体。
一种制剂,包括能与上述标志物发生特异性结合的抗体;所述制剂可用于对阿尔茨海默病进行诊断、预测、检测或筛查。
一种检测阿尔茨海默病的蛋白质芯片,该蛋白质芯片包括基片和点样在基片上特异性抗体,该特异性抗体为能与上述标志物发生特异性结合的抗体。
本发明的原理为:人体内的B淋巴细胞和T淋巴细胞是获得性免疫系统中重要的两类细胞。B细胞通过细胞表面的B细胞受体(BCR)识别抗原,后期BCR在B细胞分化成浆细胞时,表达成抗体,分泌到细胞外。T细胞通过细胞表面的T细胞受体(TCR)识别抗原。BCR和TCR的多样性是建立获得性免疫系统的基础。BCR多样性的理论值是1018,TCR多样性的理论值是1014。BCR与TCR序列中,抗原决定簇3(CDR3)是决定其抗原特异性最重要的部分,因此CDR3的序列被认为可以代表BCR、TCR序列的特性。
在各种疾病中,随着不同的抗原刺激,BCR和TCR的多样性或者表达水平都会发生改变。因此,利用BCR或者TCR高通量测序结果可以追踪疾病的发生、发展。人体内细胞中,衰老蛋白质降解后,其片段会被运输到细胞表面,通过组织相容性抗原II(MCHII)呈递给免疫系统中的T细胞。正常细胞呈递的抗原片段,由于免疫耐受的关系,不会引起免疫反应。一旦当正常细胞出现病变后,突变的基因表达的异常蛋白,其片段被呈递到细胞表面后,就会引起人体免疫系统产生针对性的免疫反应。因此,分析BCR或TCR的变化,能够检测出肿瘤或其它疾病的发生和发展。
本发明的有益效果为:
1、本发明中,首先利用1725个非阿尔茨海默病的对照组样本、和11个阿尔茨海默病病人的TCR高通量测序数据建立了大数据分析模型,通过和这些阿尔茨海默病特异性TCR序列对比,可以清楚的判断待测样本中是否有较高阿尔茨海默病风险者。
2、通过高通量测序分析TCR变化可以发现很早期的阿尔茨海默病,利用阿尔茨海默病特有的TCR CDR3序列分析人的免疫系统中的T细胞对阿尔茨海默病的反应,是一种新型的检测方法。
3、本发明通过采用高通量测序技术同时比较数量巨大的特异性TCR序列,比起单独检测一种或几种标记物,具有更高的特异性和准确性。
4、本发明中使用的高通量测序仪器成本低于大型影像学设备,且可向第三方外包,此外,采样、处理的人力成本低于同时检测多种标记物,也低于大量细胞学检测,因此,本发明大大降低了检测成本。
5、本发明只需要采取少量外周血,采样简便、安全,是一种无创检验方法。
6、本发明中所述TCR CDR3序列,可用于阿尔茨海默病的免疫治疗。
附图说明
图1为本发明中,利用基于免疫大数据分析系统发现阿尔茨海默病特征性TCR序列。横坐标代表某一特定氨基酸组合的CDR3序列被加入对照序列集合或阿尔茨海默病特征序列集合的先后顺序,纵坐标代表该序列在某一样本中重复出现次数CX的对数值;阿尔茨海默病患者的免疫图谱具有多个种类且重复次数较高的阿尔茨海默病特征序列,健康人极少阿尔茨海默病特征序列,而未知受试者的阿尔茨海默病特征比较明显,说明罹患阿尔茨海默病风险较高。
图2为本发明中,利用阿尔茨海默病特征特征性指数对比分析阿尔茨海默病和其他疾病。健康人、非神经疾病病人、非阿尔茨海默病的其它神经性疾病患者的阿尔茨海默病特征性指数均与阿尔茨海默病患者具有显著差异,证明了阿尔茨海默病特征序列集的特异性。据此可以判断未知受试者是否罹患阿尔茨海默病。
具体实施方式
下面对本发明的具体实施方式进行描述,以便于本技术领域的技术人员理解本发明,但应该清楚,本发明不限于具体实施方式的范围,对本技术领域的普通技术人员来讲,只要各种变化在所附的权利要求限定和确定的本发明的精神和范围内,这些变化是显而易见的,一切利用本发明构思的发明创造均在保护之列。
实施例1通过免疫图谱分析,获得阿尔茨海默病TCR标志物CDR3序列集
1、采样及免疫图谱分析
采集1726名对照组(包括健康人和非神经疾病病人,1725人用于建立模型,1个健康人用于验证)、12名阿尔茨海默病患者(11人用于建立模型,1人用于验证)及1名未知健康状况受试者的外周血(每人10mL),通过高通量测序得到受试者和对照组的TCR的抗原决定簇3(CDR3)氨基酸序列,保证每个样本的功能性TCR的CDR3序列总数综合不低于25000;
2、对每个功能性TCR的CDR3序列总数综合高于30000的样本的序列进行随机不放回抽样,使该样本的CDR3序列数量总和为30000。至此所有样本包含的功能性TCR的CDR3序列总数为25000-30000。对任一特定CDR3序列X,在单样本测序结果中重复出现次数计为CX;
3、通过分析TCR CDR3数据,确定阿尔茨海默病TCR标志物CDR3序列:
a)将1725名用于建立模型的对照组样本的所有CDR3序列归总去重,设为对照序列集;
b)将11名用于建立模型的阿尔茨海默病样本的所有CDR3序列归总去重,再去除所有与对照序列集中包含序列重复的序列,设为阿尔茨海默病特征序列集。作图如附图1A所示,其中横坐标代表某一特定氨基酸组合的CDR3序列被加入对照序列集合或阿尔茨海默病特征序列集合的先后顺序,纵坐标代表该序列在某一样本中重复出现次数CX的对数值。
c)按照同样作图方法,将1名健康人、1名阿尔茨海默病患者和1名健康状况未知受试者的免疫图谱,参照对照序列集合和阿尔茨海默病特征序列集合进行作图,见附图1B-D。从图中可见,阿尔茨海默病患者的免疫图谱中,含有较多种类且较高重复出现次数的阿尔茨海默病特征序列(图1B);健康人的免疫图谱中,只有极少量阿尔茨海默病特征序列(图1C);而未知健康状况受试者,有高于健康人的阿尔茨海默病特征序列,说明此人有较高风险罹患阿尔茨海默病(图1D)。
d)将阿尔茨海默病特征序列集中,将所有出现在两个及以上参与建模阿尔茨海默病样本里的CDR3序列,按“所有参与建模阿尔茨海默病样本里该序列单样本中重复出现次数CX的总和×包含该序列的参与建模阿尔茨海默病样本数”从高到低排序,排名前100者即为阿尔茨海默病TCR标志物CDR3序列,具体序列如SEQ ID NO.1~50所示。
实施例2验证阿尔茨海默病TCR标志物CDR3序列集的特异性
1、采样及免疫图谱分析
采集97名健康人、44名非神经疾病的患者26名癫痫患者、20名帕金森症患者,5名未知健康状况受试者的外周血(每人10mL),通过高通量测序得到受试者和对照组的TCR的抗原决定簇3(CDR3)氨基酸序列,保证每个样本的功能性TCR的CDR3序列总数综合不低于25000;对每个功能性TCR的CDR3序列总数综合高于30000的样本的序列进行随机不放回抽样,使该样本的CDR3序列数量总和为30000。至此所有样本包含的功能性TCR的CDR3序列总数为25000-30000。
2、根据来自实施例1的11名阿尔茨海默病患者,以及实施例2新获取的97名健康人、44名非神经疾病患者、26名癫痫患者、20名帕金森症患者,5名未知健康状况受试者的免疫图谱,分析其阿尔茨海默病特征性指数。
其中阿尔茨海默病特征性指数定义为:某个样本中,属于阿尔茨海默病特征序列集的所有CDR3序列在该样本内重复出现次数CX的总和。分析结果见下表2及附图2。阿尔茨海默病组与健康人(p=2.97E-54)、非神经疾病(p=1.07E-26)、癫痫(p=3.09E-17)、帕金森症(p=4.83E-14)都有显著差异,这证明了阿尔茨海默病特征序列集的特异性。
表2不同样本组的阿尔茨海默病特征性指数
3、分析各组的阿尔茨海默病特征指数(表3),5位未知健康状况受试者(检测样本)的阿尔茨海默病特征指数显著高于“非神经疾病”组的平均值+2×SD(2.1+2×2.3=6.7)、“癫痫”组的平均值+2×SD(2.3+2×3.1=8.6)或“帕金森症”组的平均值+2×SD(2.1+2×2.9=7.9),此5人具有较高风险罹患阿尔茨海默病。与临床体检结果对照后,这2人确为早期阿尔茨海默病患者。此实施例证明了利用阿尔茨海默病特征序列集及阿尔茨海默病特征性指数,预测受试者罹患阿尔茨海默病风险的可行性。
表3阿尔茨海默病特征性指数分析
综上所述,本发明所述阿尔茨海默病TCR标志物CDR3序列,确实具有显著的阿尔茨海默病特异性,不仅可以用于阿尔茨海默病预测受试者罹患阿尔茨海默病风险,未来还可用于阿尔茨海默病的生物免疫治疗。
序列表
<110> 成都益安博生物技术有限公司
<120> 一种阿尔茨海默病的外周血TCR标志物及其检测试剂盒和应用
<160> 50
<170> SIPOSequenceListing 1.0
<210> 1
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ala Ser Ser His Gly His Gly Leu Ala Gly Ser Glu Gln Phe
1 5 10
<210> 2
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Ala Ser Arg Asp Ser Thr Arg Glu Gln Tyr
1 5 10
<210> 3
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Ser Val Ile Leu Ala Asp Lys Tyr Asn Glu Gln Phe
1 5 10
<210> 4
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Ala Ser Ser Leu Ala Arg Val Ile Thr Gly Asn Glu Gln Phe
1 5 10
<210> 5
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Ser Ala Asn Pro Val Gly Gly Val Asn Thr Glu Ala Phe
1 5 10
<210> 6
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Ala Ser Ser Pro Ala Leu Asp Arg Arg Pro Asp Tyr Gly Tyr Thr
1 5 10 15
<210> 7
<211> 10
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Ala Ser Arg Ile Gly Phe Gly Glu Gln Tyr
1 5 10
<210> 8
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Ala Ser Arg Met Thr Gly Gly Lys Glu Thr Gln Tyr
1 5 10
<210> 9
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
Ala Ser Ser Leu Ser Gly Arg Ala Asn Ile Glu Gln Phe
1 5 10
<210> 10
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
Ala Ser Ser Leu Ala Leu Ala Gly Gly Ala Gln Asn Glu Gln Phe
1 5 10 15
<210> 11
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Ala Ser Arg Pro Gly Arg Val Asp Thr Gly Glu Leu Phe
1 5 10
<210> 12
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Ala Ser Glu Ile Gly Gly Arg Asn Thr Gly Glu Leu Phe
1 5 10
<210> 13
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Ser Ala Ser Pro Asp Tyr Asp Ser Thr Asp Thr Gln Tyr
1 5 10
<210> 14
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Ala Thr Ser Arg Asp Pro Ala Gly Leu Ala Gly Glu Gln Phe
1 5 10
<210> 15
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 15
Ala Ser Ser Val Asp Glu Thr Ser Leu Gly Gln Phe
1 5 10
<210> 16
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 16
Ala Ser Ser Ala Gly Gln Tyr Gly Thr Asp Thr Gln Tyr
1 5 10
<210> 17
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Ser Val Glu Ala Glu Thr Ser Gly Arg Gly Gly Thr Gly Glu Leu Phe
1 5 10 15
<210> 18
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 18
Ser Ala Ser Ser Pro Ile Gly Gly Ser Ser Tyr Glu Gln Tyr
1 5 10
<210> 19
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 19
Ala Trp Ser Asp Arg Ala Ala Met Thr Asp Thr Gln Tyr
1 5 10
<210> 20
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 20
Ser Ala Arg Ala Asp Arg Gln Thr Gly Ser Tyr Glu Gln Tyr
1 5 10
<210> 21
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 21
Ala Ser Lys Ser Gly Arg Met Asp Asn Glu Gln Phe
1 5 10
<210> 22
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 22
Ala Ser Ser Gln His Glu Gln Glu Glu Gly Thr Glu Ala Phe
1 5 10
<210> 23
<211> 17
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 23
Ala Ser Ser Ser Gly Gln Glu Arg Gln Gly Arg Val Tyr Thr Glu Ala
1 5 10 15
Phe
<210> 24
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 24
Ser Ala Arg Asp Gly Gly Ser Thr Asn Glu Gln Phe
1 5 10
<210> 25
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 25
Ser Ala Tyr Gly Ala Tyr Thr Ile Asn Glu Gln Phe
1 5 10
<210> 26
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 26
Ala Ser Arg Pro Thr Ser Glu Thr Ser Tyr Glu Gln Tyr
1 5 10
<210> 27
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 27
Ser Ala Arg Ser Arg Leu Leu Ala Lys Asn Ile Gln Tyr
1 5 10
<210> 28
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 28
Ser Ala Leu Ser Arg Gly Gln Tyr Asn Glu Gln Phe
1 5 10
<210> 29
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 29
Ala Thr Arg Gly Ala Ala Glu Leu Thr Tyr Glu Gln Tyr
1 5 10
<210> 30
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 30
Ala Ser Arg Glu Ala Gly Gly Arg Asp Thr Gln Tyr
1 5 10
<210> 31
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 31
Ala Ser Arg Gly Ala Gly Val Ala Tyr Asn Glu Gln Phe
1 5 10
<210> 32
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 32
Ala Ser Ser Leu Val Val Thr Ser Gly Pro Thr Asp Thr Gln Tyr
1 5 10 15
<210> 33
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 33
Ala Ser Ser Ser Ser Lys Gly Gly Gln Pro Gln His
1 5 10
<210> 34
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 34
Ala Ser Ser Phe Ser Cys Ile Cys Val Leu Thr Ala Pro
1 5 10
<210> 35
<211> 11
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 35
Ala Trp Arg Ile Gly Ser Thr Gly Glu Leu Phe
1 5 10
<210> 36
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 36
Ala Ser Ser Leu Glu His Gly Arg Asp Thr Gln Tyr
1 5 10
<210> 37
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 37
Ala Ser Ser Phe Gln Thr Phe Ser Tyr Asn Glu Gln Phe
1 5 10
<210> 38
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 38
Ala Ser Ser Met Arg Val Lys Tyr Asn Gln Pro Gln His
1 5 10
<210> 39
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 39
Ala Ser Ser Gln Glu Val Gly Trp Asn Glu Gln Phe
1 5 10
<210> 40
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 40
Ala Ser Ser Gly Arg Leu Gly Asn Tyr Gly Tyr Thr
1 5 10
<210> 41
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 41
Ala Ser Ser Leu Asp Gln Gly Thr Gln Gly Gln Tyr
1 5 10
<210> 42
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 42
Ala Ser Ser Asp Phe Pro Ser Gly Gly Ala Ser Tyr Asn Glu Gln Phe
1 5 10 15
<210> 43
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 43
Ala Ser Ser Ile Thr Ser Gly Lys Phe Asn Glu Gln Phe
1 5 10
<210> 44
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 44
Ala Trp Ser Glu Ala Ser Gly Glu Glu Thr Gln Tyr
1 5 10
<210> 45
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 45
Ala Ser Ser Val Asp Gln Gln Pro Glu Thr Gln Tyr
1 5 10
<210> 46
<211> 12
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 46
Ala Ser Ser Tyr Phe Gly Thr Ala Ser Glu Gln Tyr
1 5 10
<210> 47
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 47
Ala Ile Ser Glu Lys Ala Gly Asp Leu Asn Thr Glu Ala Phe
1 5 10
<210> 48
<211> 14
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 48
Ala Ser Ser Glu Ser Gly Thr Gly Leu His Tyr Glu Gln Tyr
1 5 10
<210> 49
<211> 16
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 49
Ala Ser Ser Gln Ala Asp Trp Ala Gly Gly Arg His Asn Gly Gln Phe
1 5 10 15
<210> 50
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 50
Ala Ser Ser Arg Thr Gly Gly Gly Gly Arg Glu Leu Phe
1 5 10
Claims (7)
1.一种阿尔茨海默病的外周血TCR标志物,其特征在于,所述标志物包括序列为SEQ IDNO.1~50所示的蛋白中的至少一种。
2.根据权利要求1所述的阿尔茨海默病的外周血TCR标志物,其特征在于,所述标志物的蛋白序列为SEQ ID NO.1~50所示的序列经取代、缺失和/或替换一个或多个氨基酸后,能实现相同功能的蛋白。
3.权利要求1所述的标志物在制备治疗阿尔茨海默病的制剂中的应用。
4.根据权利要求3所述的应用,其特征在于,所述制剂包括含有该TCR标志物的T细胞受体,或能表达产生该标志物的T细胞受体的质粒、病毒载体或核酸片段。
5.一种用于阿尔茨海默病检测的试剂盒,其特征在于,包括能与权利要求1所述TCR标志物发生特异性结合的抗体。
6.一种制剂,其特征在于,包括能与权利要求1所述TCR标志物发生特异性结合的抗体;所述制剂可用于对阿尔茨海默病进行诊断、预测、检测或筛查。
7.一种检测阿尔茨海默病的蛋白质芯片,其特征在于,所述蛋白质芯片包括基片和点样在基片上特异性抗体,所述特异性抗体为能与权利要求1所述TCR标志物发生特异性结合的抗体。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110835011.1A CN113567682A (zh) | 2021-07-23 | 2021-07-23 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
PCT/CN2022/080368 WO2023000688A1 (zh) | 2021-07-23 | 2022-03-11 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110835011.1A CN113567682A (zh) | 2021-07-23 | 2021-07-23 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113567682A true CN113567682A (zh) | 2021-10-29 |
Family
ID=78166639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110835011.1A Pending CN113567682A (zh) | 2021-07-23 | 2021-07-23 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN113567682A (zh) |
WO (1) | WO2023000688A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023000688A1 (zh) * | 2021-07-23 | 2023-01-26 | 成都益安博生物技术有限公司 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009014342A2 (en) * | 2007-07-20 | 2009-01-29 | Young In Frontier Co., Ltd. | Markers and kit for diagnosis of alzheimer's disease |
WO2018221212A1 (ja) * | 2017-05-31 | 2018-12-06 | 公立大学法人名古屋市立大学 | アルツハイマー病バイオマーカー |
CN111624340A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种胰腺癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111624342A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种卵巢癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111624341A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种子宫内膜癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111624339A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种肝癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111650373A (zh) * | 2020-07-11 | 2020-09-11 | 成都益安博生物技术有限公司 | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111665359A (zh) * | 2020-07-11 | 2020-09-15 | 成都益安博生物技术有限公司 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111679074A (zh) * | 2020-07-11 | 2020-09-18 | 成都益安博生物技术有限公司 | 一种前列腺癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111693702A (zh) * | 2020-07-11 | 2020-09-22 | 成都益安博生物技术有限公司 | 一种黑色素瘤的外周血tcr标志物及其检测试剂盒和应用 |
CN111693701A (zh) * | 2020-07-11 | 2020-09-22 | 成都益安博生物技术有限公司 | 一种大肠癌的外周血tcr标志物序列及其检测试剂盒和应用 |
CN111812325A (zh) * | 2020-07-11 | 2020-10-23 | 成都益安博生物技术有限公司 | 一种乳腺癌的外周血tcr标志物及其检测试剂盒和应用 |
JP2021012094A (ja) * | 2019-07-05 | 2021-02-04 | 公立大学法人名古屋市立大学 | アルツハイマー病又は発症前アルツハイマー病の診断用マーカー及び診断用キット、脳内へのアミロイドβタンパク質の蓄積量の評価方法、並びに被験者におけるアルツハイマー病又は発症前アルツハイマー病の検出を補助するためのインビトロの方法 |
CN112321700A (zh) * | 2020-09-21 | 2021-02-05 | 四川省人民医院 | 一种新型冠状病毒感染的外周血tcr标志物及其检测试剂盒和应用 |
CN113030473A (zh) * | 2021-03-15 | 2021-06-25 | 成都益安博生物技术有限公司 | 一种急性b淋巴细胞白血病的外周血tcr标志物及其检测试剂盒和应用 |
CN113092761A (zh) * | 2021-03-15 | 2021-07-09 | 成都益安博生物技术有限公司 | 一种弥漫大b细胞淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 |
CN113109564A (zh) * | 2021-03-15 | 2021-07-13 | 成都益安博生物技术有限公司 | 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用 |
CN113125724A (zh) * | 2021-03-15 | 2021-07-16 | 成都益安博生物技术有限公司 | 一种经典霍奇金淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002040023A (ja) * | 2000-07-28 | 2002-02-06 | Mitsubishi Chemicals Corp | アルツハイマー病の検出方法 |
EP1934618B1 (en) * | 2005-10-11 | 2009-05-13 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb) |
FR3002044A1 (fr) * | 2013-02-08 | 2014-08-15 | Centre Nat Rech Scient | Marqueur dyrk1a pour la maladie d'alzheimer |
WO2020031116A1 (en) * | 2018-08-08 | 2020-02-13 | Seoul National University R&Db Foundation | Method of diagnosing and treating alzheimer disease using plasma tau level in conjunt ion with beta-amyloid level as diagnostic index |
CN112695084A (zh) * | 2021-02-08 | 2021-04-23 | 山东大学第二医院 | 诊断阿尔茨海默病和阿尔茨海默病进展的生物标志物及应用 |
CN113567682A (zh) * | 2021-07-23 | 2021-10-29 | 成都益安博生物技术有限公司 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
-
2021
- 2021-07-23 CN CN202110835011.1A patent/CN113567682A/zh active Pending
-
2022
- 2022-03-11 WO PCT/CN2022/080368 patent/WO2023000688A1/zh unknown
Patent Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009014342A2 (en) * | 2007-07-20 | 2009-01-29 | Young In Frontier Co., Ltd. | Markers and kit for diagnosis of alzheimer's disease |
WO2018221212A1 (ja) * | 2017-05-31 | 2018-12-06 | 公立大学法人名古屋市立大学 | アルツハイマー病バイオマーカー |
JP2021012094A (ja) * | 2019-07-05 | 2021-02-04 | 公立大学法人名古屋市立大学 | アルツハイマー病又は発症前アルツハイマー病の診断用マーカー及び診断用キット、脳内へのアミロイドβタンパク質の蓄積量の評価方法、並びに被験者におけるアルツハイマー病又は発症前アルツハイマー病の検出を補助するためのインビトロの方法 |
CN111624341A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种子宫内膜癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111693701A (zh) * | 2020-07-11 | 2020-09-22 | 成都益安博生物技术有限公司 | 一种大肠癌的外周血tcr标志物序列及其检测试剂盒和应用 |
CN111624339A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种肝癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111650373A (zh) * | 2020-07-11 | 2020-09-11 | 成都益安博生物技术有限公司 | 一种宫颈癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111665359A (zh) * | 2020-07-11 | 2020-09-15 | 成都益安博生物技术有限公司 | 一种肺癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111679074A (zh) * | 2020-07-11 | 2020-09-18 | 成都益安博生物技术有限公司 | 一种前列腺癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111693702A (zh) * | 2020-07-11 | 2020-09-22 | 成都益安博生物技术有限公司 | 一种黑色素瘤的外周血tcr标志物及其检测试剂盒和应用 |
CN111624342A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种卵巢癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111812325A (zh) * | 2020-07-11 | 2020-10-23 | 成都益安博生物技术有限公司 | 一种乳腺癌的外周血tcr标志物及其检测试剂盒和应用 |
CN111624340A (zh) * | 2020-07-11 | 2020-09-04 | 成都益安博生物技术有限公司 | 一种胰腺癌的外周血tcr标志物及其检测试剂盒和应用 |
CN112321700A (zh) * | 2020-09-21 | 2021-02-05 | 四川省人民医院 | 一种新型冠状病毒感染的外周血tcr标志物及其检测试剂盒和应用 |
CN113030473A (zh) * | 2021-03-15 | 2021-06-25 | 成都益安博生物技术有限公司 | 一种急性b淋巴细胞白血病的外周血tcr标志物及其检测试剂盒和应用 |
CN113092761A (zh) * | 2021-03-15 | 2021-07-09 | 成都益安博生物技术有限公司 | 一种弥漫大b细胞淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 |
CN113109564A (zh) * | 2021-03-15 | 2021-07-13 | 成都益安博生物技术有限公司 | 一种急性髓细胞性白血病的外周血tcr标志物及其检测试剂盒和应用 |
CN113125724A (zh) * | 2021-03-15 | 2021-07-16 | 成都益安博生物技术有限公司 | 一种经典霍奇金淋巴瘤的外周血tcr标志物及其检测试剂盒和应用 |
Non-Patent Citations (1)
Title |
---|
MARIA ALISEYCHIK等: "Dissection of the Human T-Cell Receptor γ Gene Repertoire in the Brain and Peripheral Blood Identifies Age- and Alzheimer’s Disease-Associated Clonotype Profiles", 《FRONTIERS IN IMMUNOLOGY》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023000688A1 (zh) * | 2021-07-23 | 2023-01-26 | 成都益安博生物技术有限公司 | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 |
Also Published As
Publication number | Publication date |
---|---|
WO2023000688A1 (zh) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Doppler et al. | Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson’s disease | |
Maciag et al. | Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies | |
JP4659025B2 (ja) | 神経系傷害および他の神経障害についての生物マーカーとしての神経タンパク質 | |
EP2836844B1 (en) | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases | |
US20140303041A1 (en) | In vitro diagnostic devices for nervous system injury and other neural disorders | |
CN102933966A (zh) | 阿尔茨海默病的新型诊断制剂 | |
Wallon et al. | Clinical and neuropathological diversity of tauopathy in MAPT duplication carriers | |
CN113567682A (zh) | 一种阿尔茨海默病的外周血tcr标志物及其检测试剂盒和应用 | |
Vijiaratnam et al. | How should we be using biomarkers in trials of disease modification in Parkinson’s disease? | |
Spinella et al. | Research initiatives on Machado‐Joseph disease: National Institute of Neurological Disorders and Stroke Workshop summary—meeting summary | |
JP6839854B2 (ja) | 星状細胞トラウマトーム(traumatome)および神経外傷のバイオマーカー | |
US20120295281A1 (en) | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases | |
Turck et al. | The quest for brain disorder biomarkers | |
US20220260595A1 (en) | A biomarker for alzheimer's disease using blood samples from clinically diagnosed alzheimer's disease subjects | |
Mossello et al. | Biomarkers of Alzheimer's disease: from central nervous system to periphery? | |
TW202136297A (zh) | Tau蛋白病變及失智症相關疾病之判定藥及判定方法 | |
JP4925063B2 (ja) | 片頭痛の診断マーカー及びその利用 | |
Fang et al. | Genetic mechanisms underlying gray matter atrophy in Parkinson’s disease: a combined transcriptome and neuroimaging study | |
Abdelmoaty et al. | Clinical biomarkers for Lewy body diseases | |
Chen et al. | Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers | |
Zhou et al. | Spatial Distribution and Hierarchical Clustering of β-Amyloid and Glucose Metabolism in Alzheimer’s Disease | |
Gonon | STUDY ON BLOOD PROTEIN MARKERS OFALZHEIMER'S | |
Wu et al. | The Phenotypic and Genotypic Spectrum of CSF1R‐Related Disorder in China | |
Hecker et al. | Multiple Sklerose I | |
KR101873971B1 (ko) | 뉴레귤린-1 단백질을 이용한 알츠하이머 병 진단용 조성물 및 이를 이용한 알츠하이머 병의 진단방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |